UNIVERCELLS

📢 PRESS RELEASE 📢 Quantoom Biosciences is proud to announce a research collaboration with the University of Arizona Health Sciences, joining forces to advance the development of an mRNA-based neoantigen cancer vaccine platform. 🧬🦠 This groundbreaking project unites the cutting-edge neoantigen prediction expertise of the Center for Advanced Molecular and Immunological Therapies (CAMI) with Quantoom’s fully integrated RNA production and formulation technologies — Ntensify® and Ncapsulate® QCX. Together, we are setting the stage for a transformative approach to melanoma treatment, harnessing the power of RNA and precision antigen science. 🎙️ We are especially inspired by the words of Ryan Sprissler, PhD, associate director for the Center for Advanced Molecular and Immunological Therapies at the University of Arizona Health Sciences and associate research professor at the university’s BIO5 Institute: “It is incredibly exciting to be working with such an innovative and experienced company like Quantoom on a technology that has shown early success and promise in its ability to change the future of cancer treatment.” Read the full press release: https://shorturl.at/0b2tM #QuantoomBiosciences #RNAInnovation #CancerVaccine #Collaboration #mRNA #Neoantigen #Ntensify #Ncapsulate #OncologyResearch #CAMI #UniversityOfArizona #Biotech #RNAtherapy #Immunotherapy #Partnership #FutureOfMedicine

🚀 PRESS RELEASE We’re proud to announce a strategic collaboration with DIANT Pharma Inc. to reshape the future of mRNA therapeutics. This partnership unites Quantoom Biosciences end-to-end mRNA production expertise with DIANT’s advanced LNP formulation technology — paving the way for a faster, simpler, and more scalable manufacturing process. With innovation at our core and patients in mind, we’re proud to be shaping the next generation of RNA-based medicine. 🔗 Learn more: https://shorturl.at/SvK45 #Quantoom #DIANTPharma #mRNA #LNP #biotech #RNArevolution #NextGenTherapies #InnovationInBiotech

🚀 PRESS RELEASE: The Pirbright Institute Adopts Quantoom’s Ntensify® mini for mRNA Vaccine Research! We’re thrilled to announce that The Centre for Veterinary Vaccine Innovation and Manufacturing (CVIM), part of The Pirbright Institute, has adopted Quantoom Biosciences’ Ntensify® mini to advance its mRNA and saRNA vaccine development at its UK site! With Ntensify® mini, The Pirbright Institute will have a research-grade mRNA and saRNA production platform that will enable cost-effective, high-quality RNA synthesis and purification, significantly accelerating the institute’s ability to develop next-generation vaccines. 💡 Want to learn more? Read the full press release here: https://shorturl.at/aHu9c #RNARevolution #VaccineInnovation #mRNA #saRNA #AnimalHealth #OneHealth #Biotech #PirbrightInstitute #Quantoom #Ntensify

As the year draws to a close, we want to take a moment to reflect and express our gratitude. To our colleagues and partners: thank you for your inspiration, collaboration, and shared efforts in driving innovation in biotech throughout this year! Together, we’ve taken meaningful steps to advance our shared purpose: to transform how biotech drugs are made so that everyone, everywhere, can get them. As we look ahead to 2025, we remain driven by this mission and inspired by the people who make it possible. Thank you for your dedication and trust. Wishing you a peaceful and joyful holiday season! #BiotechInnovation #Collaboration #ThankYou

We’re proud to see our partnership with the Oxford Vaccine Group, the Pandemic Sciences Institute, and Oxford Cancer highlighted as one of Nuffield Department of Medicine’s top five stories of 2024. It’s also been one of the highlights of our year! Together, we’re advancing the development of RNA vaccines for cancer and infectious diseases - accelerating access to life-saving solutions where they’re needed most. #BiotechInnovation #RNAVaccines #AccessToTherapies

Inside Wallonia-Brussels’ Expertise: Limelight on UK–Belgium Collaboration in Life Sciences Listen to UNIVERCELLS Chief Alliance Officer, Hala Audi, delve into the strengths of the growing partnership between Belgium and the UK in the rapidly advancing field of #RNA-based therapies – an innovative approach that holds great promise for tackling complex diseases including cancer. We investigate the exciting collaboration between Univercells, the Oxford Vaccine Group, the Pandemic Sciences Institute and @Oxford Cancer, highlighting landmark milestones and future prospects. This partnership represents a significant step forward in advancing cancer treatment and unlocking new opportunities for #lifesciences ecosystems in both Belgium and the UK. #LifeSciences #RNATherapies #UKBelgiumPartnership #Collaboration #Healthcare #CancerResearch #UKBelgiumCollaboration #Innovation #Biotech #HealthcareTransformation Wallonie Bruxelles International Wallonie-Bruxelles International - Research and Innovation Loïc Lefevre Motonobu Kasajima AWEX UK University of Liège Université libre de Bruxelles UMONS MedReSyst University of Oxford Imperial College London UCB 📸 by J. Van Belle - WBI

📍Boston, this week. We’re at the Personalized Cancer Vaccine Summit - a gathering of visionaries shaping the future of oncology. Why are we here? Because the promise of personalized cancer vaccines aligns with what drives us: transforming innovation into accessible reality. These therapies hold the power to tailor treatments to individual patients, offering hope where it's needed most. At UNIVERCELLS, our proprietary RNA technology and expertise across mRNA molecular design and optimization, DNA manufacturing, to delivery formulation, and a robust mRNA-agnostic manufacturing process can help revolutionize how these cutting-edge therapies are made. By overcoming the barriers of complexity, cost, and time, we can help to bring life-saving solutions to more patients, faster. Let’s connect. Whether you're in Boston or following the event remotely, we’d love to explore how we can collaborate to make it happen. Reach out to Hela Kallel and Lionel MALBEC to explore how we can reimagine cancer care. Together, we can make a difference. #RNATechnology #BiotechInnovation #PersonalizedTreatment 

Recap of an Eventful Week at the Belgian Economic Mission to Brazil 🇧🇪🇧🇷 The Belgian Economic Mission to Brazil (22 Nov. - 1 Dec.) was a week full of remarkable moments for UNIVERCELLS and Quantoom Biosciences represented by Jose Castillo and Maria Davila-Saignol, but two key events on Friday, November 29, stood out as highlights: ✨ Private Meeting with HRH Princess Astrid: We were honored to participate in a special session to present the details of the agreement signed between Bio-Manguinhos / Fiocruz, Univercells and Quantoom Biosciences. This successful partnership is a testament to the strength of Belgium-Brazil collaboration, focusing on RNA-based therapies and local biopharma capacity building. ➠ Read the press release: https://shorturl.at/k6QiZ In addition to HRH Princess Astrid, notable attendees included: • HE Dirk Wouters , Ambassador of Belgium in Washington DC • HE Peter Claes, Ambassador of Belgium in Brazil • Pascale Delcomminette, CEO of AWEX • Caroline Mouchart, Belgian Consul General in Rio de Janeiro • Brent Van Tassel, Economic Advisor to his Majesty the King • Mario Moreira, President of Fiocruz • Mauricio Zuma, CEO of Bio-Manguinhos • Ricardo de Godoi Mattos Ferreira, Vice Director of Innovation at BioManguihnos  • Patrícia Neves, Scientific Leader and Project Manager - HUBRNA • Rodrigo dos SANTOS A. GARCIA, Economic and Commercial Counselor at AWEX • Fabienne L'Hoost, Director General at Belgian Foreign Trade Agency ✨ Seminar on Epidemics and Vaccine Resilience: During this seminar on “The Future of Epidemics and the Future of Vaccines,” Jose Castillo presented on “Scalable and Integrated mRNA Vaccine Manufacturing: Endemic Facility with Pandemic Resilience.” The session emphasized our vision for sustainable and innovative vaccine production systems, critical for future health challenges. Other highlights from the mission included a warm kick-off in São Paulo, engaging meetings with Brazil’s Vice President Geraldo Alckmin, collaborative discussions at Hospital Albert Einstein, and the signing of a Memorandum of Understanding in Rio de Janeiro, marking a milestone in Belgium-Brazil biotech collaboration. ✨ Special Thanks: A heartfelt thank you to Wallonia Export & Investment Agency, Wallonie Bruxelles International, Embaixada Do Reino da Bélgica no Brasil, Consulado Geral da Bélgica, Consulado Geral da Bélgica no Rio de Janeiro, and Bio-Manguinhos / Fiocruz for their outstanding organization and coordination throughout this inspiring mission. 🌍 Together, we are shaping the future of health innovation! #BEmissionBRA #BiotechInnovation #PartneringForGlobalHealth #BelgiumBrazilRelations #HealthcareInnovation

What drives progress in biotech innovation and global health? At UNIVERCELLS, we believe it’s the power of partnerships. That’s why this week, alongside Quantoom Biosciences, we enthusiastically joined Bio-Manguinhos / Fiocruz and FIOCRUZ - Fundação Oswaldo Cruz in a Memorandum of Understanding (MoU). It was signed by Jose Castillo, our Chief Technology Officer, and Mauricio Zuma, CEO of Bio-Manguinhos in the presence of HRH Princess Astrid of Belgium, during the Belgian Economic Mission to Brazil. By uniting our expertise across borders, we aim to accelerate progress in novel RNA-based vaccines and therapies. Together, we will: 🔬 Develop next-generation saRNA vaccines for regional and global impact. 🤝 Co-create RNA-based therapies to tackle diseases like cancer. 🌍 Explore “One Health” solutions for both human and animal health. 🏭 Establish an mRNA manufacturing facility in Brazil, empowering local biopharma production. Learn more about our collaboration here: https://lnkd.in/egpe4gcD #BiotechInnovation #PartneringForGlobalHealth #BEmissionBRA

Exciting Updates from the Belgian Economic Mission in Brazil! 🇧🇪🇧🇷 UNIVERCELLS and Quantoom Biosciences were honored to have Jose Castillo and Maria Davila-Saignol representing both companies during an official meeting in São Paulo with Her Royal Highness Princess Astrid of Belgium and His Excellency Geraldo Alckmin, Vice President of Brazil. This special gathering, held last Tuesday, provided an opportunity for selected CEOs from Belgian companies to present their innovations and expertise—a proud moment for all participants! The same day, we were thrilled to engage in a dynamic B2B pitching session at the renowned Hospital Albert Einstein (HIAE) in São Paulo. This inspiring event brought together key stakeholders in healthcare and biotech for meaningful discussions and potential collaborations. 🤝 A heartfelt thank you to Dr. Miguel Cendoroglo Neto (HIAE, CMO), Dr. Caroline Kanaan (Medical Lead,HIAE), Dr. Vanessa Teich (Director of Oncology and Hematology), Dr. Eliézer Silva (COO, HIAE), Xavier Hormaechea (Managing Director, UCB Belgium, Head of EU Corporate Affairs), Michel Conte (Country Lead at UCB Brazil), Laurent Bernard (Inward Investment Manager at AWEX), and Rodrigo dos SANTOS A. GARCIA (Economic and Commercial Counselor at AWEX) for the warm hospitality and the exceptional organization 🙏 This mission underscores the power of international cooperation, innovation, and shared vision. 🌍✨ #BEmissionBRA #Innovation #BelgiumBrazilRelations #HealthcareInnovation